- Home
- LIXT vs ATCH Comparison
LIXT vs ATCH Comparison
Compare LIXT & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- ATCH
- Stock Information
- Founded
- LIXT 2005
- ATCH 2022
- Country
- LIXT United States
- ATCH United States
- Employees
- LIXT N/A
- ATCH N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- ATCH
- Sector
- LIXT Health Care
- ATCH
- Exchange
- LIXT Nasdaq
- ATCH Nasdaq
- Market Cap
- LIXT 12.4M
- ATCH 2.5M
- IPO Year
- LIXT N/A
- ATCH N/A
- Fundamental
- Price
- LIXT $3.41
- ATCH $0.19
- Analyst Decision
- LIXT
- ATCH
- Analyst Count
- LIXT 0
- ATCH 0
- Target Price
- LIXT N/A
- ATCH N/A
- AVG Volume (30 Days)
- LIXT 136.6K
- ATCH 33.6M
- Earning Date
- LIXT 08-07-2025
- ATCH 09-02-2025
- Dividend Yield
- LIXT N/A
- ATCH N/A
- EPS Growth
- LIXT N/A
- ATCH N/A
- EPS
- LIXT N/A
- ATCH N/A
- Revenue
- LIXT N/A
- ATCH $14,825,966.00
- Revenue This Year
- LIXT N/A
- ATCH N/A
- Revenue Next Year
- LIXT N/A
- ATCH N/A
- P/E Ratio
- LIXT N/A
- ATCH N/A
- Revenue Growth
- LIXT N/A
- ATCH 1066.77
- 52 Week Low
- LIXT $0.64
- ATCH $0.14
- 52 Week High
- LIXT $5.14
- ATCH $26.94
- Technical
- Relative Strength Index (RSI)
- LIXT 44.33
- ATCH 49.97
- Support Level
- LIXT $3.13
- ATCH $0.17
- Resistance Level
- LIXT $4.04
- ATCH $0.25
- Average True Range (ATR)
- LIXT 0.57
- ATCH 0.03
- MACD
- LIXT -0.22
- ATCH 0.00
- Stochastic Oscillator
- LIXT 16.66
- ATCH 39.28
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.